Clinical trials: Plaque-type Psoriasis
Psoriasis
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.
- Trial name
- ADVANCE (NCT03721172)
- Testing
- Apremilast
- Where
- 64 sites in United States, Canada
- Volunteers
- 595 people
- Sponsor
- Amgen
Psoriasis
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis.
- Trial name
- VOYAGE 1 (NCT02207231)
- Testing
- Guselkumab 100 mg, Adalimumab
- Where
- 97 sites in United States, Australia and 8 more
- Volunteers
- 837 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis
Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab
The purpose of this study was to explore the effect of treatment with 300 mg or with 150 mg secukinumab (administered weekly for 4 weeks followed by four-weekly administration) on endothelial dysfunction and arterial stiffness…
- Trial name
- CARIMA (NCT02559622)
- Testing
- Secukinumab
- Where
- 23 sites in Germany
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis
There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study.
- Trial name
- PSOR-003 (NCT00606450)
- Testing
- CC-10004
- Where
- 31 sites in Canada, Czechia and 1 more
- Volunteers
- 260 people
- Sponsor
- Amgen
Chronic Plaque Psoriasis
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- FIXTURE (NCT01358578)
- Testing
- secukinumab (AIN457), etanercept
- Where
- 152 sites in United States, Argentina and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis-Type Psoriasis, Plaque-Type Psoriasis
Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis
The study will test the safety and tolerability of Apremilast twice a day in participants with recalcitrant plaque type psoriasis.
- Trial name
- NCT00521339
- Testing
- Apremilast
- Where
- 4 sites in United States
- Volunteers
- 31 people
- Sponsor
- Amgen
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Psoriasis Vulgaris, Psoriasis
Tofacitinib Ointment For Chronic Plaque Psoriasis
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested.
- Trial name
- NCT01831466
- Testing
- tofacitinib ointment 20 mg/g, tofacitinib ointment 10 mg/g
- Where
- 54 sites in United States, Canada and 2 more
- Volunteers
- 476 people
- Sponsor
- Pfizer
Psoriasis
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.
- Trial name
- NCT01139580
- Testing
- Calcipotriene Foam, Vehicle Foam
- Where
- 26 sites in United States
- Volunteers
- 363 people
- Sponsor
- Stiefel, a GSK Company
Plaque Type Psorisis
Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis
To compare the safety and efficacy of the test (Tapinarof Cream 1%), placebo (vehicle cream) and reference VTAMA® (Tapinarof Cream 1%) treatments to demonstrate clinical equivalence in patients with plaque psoriasis.
- Trial name
- NCT06742957
- Testing
- Tapinarof Cream 1%, VTAMA®
- Where
- 26 sites in United States
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Psoriasis
A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to evaluate the efficacy and safety of Ustekinumab in the treatment of patients with moderate to severe psoriasis in South Korea and Taiwan.
- Trial name
- NCT00747344
- Testing
- Ustekinumab 45 mg - CP, Ustekinumab 45 mg - after CP
- Where
- 5 sites in South Korea, Taiwan
- Volunteers
- 121 people
- Sponsor
- Centocor, Inc.
Plaque-type Psoriasis
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis
The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin.
- Trial name
- AN2728-PSR-104 (NCT01258088)
- Testing
- AN2728 Ointment, AN2728 Vehicle
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriasis
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01309737
- Testing
- CP-690,550
- Where
- 94 sites in United States, Canada and 9 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Plaque Psoriasis
TSO for Plaque Psoriasis
This is a randomized, blinded, multicenter study to assess the safety and treatment effect of 12 weeks of Trichuris suis ova in subjects diagnosed with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT02011269
- Testing
- Trichuris Suis Ova
- Sponsor
- Coronado Biosciences, Inc.
Psoriasis
Observational Study Evaluating Etanercept (Enbrel®) In Subjects With Plaque-Type Psoriasis In Usual Care Settings
This prospective observational cohort study will assess the average duration of the drug free interval between etanercept treatment cycles in usual care settings in Germany.
- Trial name
- NCT00708708
- Testing
- etanercept (Enbrel®)
- Where
- Germany
- Volunteers
- 926 people
- Sponsor
- Pfizer
Chronic Severe Plaque-type Psoriasis
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis.
- Trial name
- NCT02471144
- Testing
- Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Active Comparator: Etanercept
- Where
- 46 sites in United States, Belgium and 17 more
- Volunteers
- 162 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis, Plaque
A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis
The purpose of this study is to assess the severity of plaque-type psoriasis (common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches.
- Trial name
- NCT02274363
- Testing
- No Intervention
- Where
- 16 sites in Brazil
- Volunteers
- 1,131 people
- Sponsor
- Janssen Pharmaceutica
Psoriasis
Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis
GSK2981278 is a highly potent and selective inverse agonist of retinoic acid receptor-related orphan receptor gamma (ROR gamma) that is under development for topical treatment of plaque type psoriasis suitable for topical…
- Trial name
- NCT02548052
- Testing
- GSK2981278 0.03%, GSK2981278 0.1%, GSK2981278 0.8%
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Chronic Plaque Psoriasis
Multiple-loading Dose Regimen Study in Patients With Chronic Plaque-type Psoriasis
Loading dose, four arm, double-blind, parallel group, placebo-controlled study comparing single and multiple doses of AIN457 to placebo in patients with a diagnosis of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00805480
- Testing
- AIN457
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals